Marshall Edwards taps new president and CEO

Marshall Edwards has announced that Daniel Gold has been appointed president and CEO of the company. Release

Amgen has appointed Robert Bradway president and COO, effective May 11. Release

Allos Therapeutics has named Charles Morris as executive VP, chief medical officer. In his position, Morris will lead the company's clinical development functions, including clinical operations, medical affairs, regulatory and biometrics. Release

Dutch vaccine development company MUCOSIS has announced that Roberto Grimaldi was appointed the company's CMO. Release

Satori Pharmaceuticals Incorporated, a privately held developer of therapeutics for Alzheimer's disease, has announced the election of Steven Holtzman to chair of its board of directors and the appointment of Jeff Jonker as its chief business officer. Release

Opexa Therapeutics has hired Donald Healey, an experienced cell therapy immunologist, to lead the company's R&D efforts including the further development of Tovaxin. Release

Mike Burgess named head of oncology discovery translational area for Roche's Pharma Research and Early Development Organization. Release

Elizabeth "Libby" Hart-Wells has been named assistant vice president and director of the Office of Technology Commercialization at Purdue Research Foundation. Release

Arrowhead Research has tapped former FDA Commissioner Andrew von Eschenbach to its scientific advisory board. Release

 PharmAthene a biodefense company developing medical countermeasures against biological and chemical threats, announced the appointment of Mitchel Sayare to PharmAthene's board. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.